The latest announcement is out from InMed Pharmaceuticals (INM).
Dr. David G. Morgan, an esteemed expert in neurodegenerative disease, has joined the Scientific Advisory Board of a company, boosting their endeavors to develop their INM-901 program for Alzheimer’s treatment. This strategic addition underscores the company’s dedication to making significant strides in the fight against this challenging condition.
For detailed information about INM stock, go to TipRanks’ Stock Analysis page.
